On 17 June, AriBio - a clinical-stage biopharmaceutical company developing innovative drugs for specific diseases including neurodegenerative and infectious diseases - announced the completion of enrolment of its Phase II study of AR1001 for Alzheimer’s disease (AD). The Phase II study is a double-blind, randomised and placebo-controlled trial evaluating the efficacy and safety of AR1001 in people with mild to moderate AD. A total of 210 US research participants received placebo or AR1001 orally, once daily over 26 weeks. The company is expecting to announce the topline results by early 2021 and to initiate another Phase II study for mixed dementia in 2021.
